Prediabetes is associated with abnormal circadian blood pressure variability

Journal of Human Hypertension

Volumn 22, Issue 9, 2008, Pages 627-633

  Gupta, A K ^a   Greenway, F L ^a   Cornelissen, G ^b   Pan, W ^a   Halberg, F ^b  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE VARIABILITY; BODY MASS; CARDIOVASCULAR RISK; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; MALE; METABOLIC SYNDROME X; SCREENING TEST; WAIST CIRCUMFERENCE;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CIRCADIAN RHYTHM; DIABETES MELLITUS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDIABETIC STATE; WEIGHT LOSS;

EID: 50449099127     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2008.32     Document Type: Article

References (46)

1. Halberg F, Conner RL. Circadian organization and microbiology: Variance spectra and a periodogram on behavior of Escherichia coli growing in fluid culture. Proc Minn Acad Sci 1961; 29: 227-239.
2. Halberg F, Cornélissen G, Katinas G, Tvildiani L, Gigolashvili M, Janashia K et al. International BIOCOS Group. Chronobiology's progress: Season's appreciations 2004-2005. Time, frequency, phase, variable, individual, age- and site-specific chronomics. J Appl Biomed 2006; 4: 1-38.
3. Halberg F, Cornélissen G, Katinas G, Tvildiani L, Gigolashvili M, Janashia K et al. International BIOCOS Group. Chronobiology's progress: Part II, chronomics for an immediately applicable biomedicine. J Appl Biomed 2006; 4: 73-86.
4. Yamamoto T, Nakahata Y, Soma H, Akashi M, Mamine T, Takumi T. Transcriptional oscillation of canonical clock genes in mouse peripheral tissues. BMC Mol Biol 2004; 5: 18. doi:10.1186/ 1471-2199-5-18.
5. Haus E. Chrbnobiology in the endocrine system. Adv Drug Deliv Rev 2007; 59: 985-1014.
6. O'Brien E. Ambulatory blood pressure measurement: A trove of hidden gems? Hypertension 2006; 48: 364-365.
7. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 1999; 282: 530-546.
8. White WB. How well does ambulatory blood pressure predict target-organ disease and clinical outcome in patients with hypertension? Blood Press Monit 1999; 4(Suppl 2): S17-S21 (review).
9. Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Type 2 diabetes as a 'coronary heart disease equivalent': An 18-year prospective population-based study in Finnish subjects. Diabetes Care 2005; 28: 2901-2907.
10. Whiteley L, Padmanabhan S, Hole D, Isles C. Should diabetes be considered a coronary heart disease risk equivalent?: Results from 25 years of follow-up in the Renfrew and Paisley survey. Diabetes Care 2005; 28: 1588-1593.
11. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in the diabetes control in insulin dependent diabetes mellitus. N Engl J Med 329: 977-986.
12. Nielson C, Lange T, Hadjokas N. Blood glucose and coronary artery disease in nondiabetic patients. Diabetes Care 2006: 29: 998-1001.
13. Schnell O, Staudl E. Impaired glucose tolerance, diabetes, and cardiovascular disease. Endocr Pract 2006; 12(Suppl 1): 16-19.
14. Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: The Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007; 116: 151-157.
15. Diamantopoulos EJ, Andreadis EA, Tsourous GI, Katsanou PM, Georgiopoulos DX, Nestora KC et al. Early vascular lesions in subjects with metabolic syndrome and prediabetes. Int Angiol 2006; 25: 179-183.
16. Meigs JB, Larson MG, D'Agostino RB, Levy D, Clouse ME, Nathan DM et al. Coronary artery calcification in type 2 diabetes and insulin resistance: The Framingham offspring study. Diabetes Care 2002; 25: 1313-1319.
17. Kim SH, Reaven GM. The metabolic syndrome: One step forward, two steps back. Diab Vasc Dis Res 2004; 1: 68-75.
18. Reaven GM. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med 2005; 47: 201-210.
19. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004; 109: 42-46.
20. Bingham C, Arbogast B, Guillaume GC, Lee JK, Halberg F. Inferential statistical methods for estimating and comparing cosinor parameters. Chronobiologia 1982; 9: 397-439.
21. Zaslavskaya RM. Chronodiagnosis and chronotherapy of cardiovascular diseases, 2nd edn. Translation into English from Russian Medicina: Moscow, 1993, pp 397.
22. Katinas GS, Cornélissen G, Otsuka K, Haus E, Bakken EE, Halberg F. Why continued surveillance? Intermittent blood pressure and heart rate abnormality under treatment. Biomed Pharmacother 2005; 59 (Suppl 1): S141-S151. Diabetes Care. 1999; 22:233-40.
23. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A meta regression analysis of published data from 20 studies of 95 783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 1385-1387.
24. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. National Heart, Lung, and Blood Institute Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003; 289: 2560-2572.
25. Stolarz K, Staessen JA, O'Brien ET. Night-time blood pressure: Dipping into the future? J Hypertens 2002; 20: 2131-2133 (review).
26. Giles TD. Circadian rhythm of blood pressure and the relation to cardiovascular events. J Hypertens Suppl 2006; 24: S11-S16 (review).
27. Jerrard-Dunne P, Mahmud A, Feely J. Circadian blood pressure variation: relationship between dipper status and measures of arterial stiffness. J Hypertens 2007; 25: 1233-1239.
28. Hermida RC, Ayala DE, Portaluppi F. Circadian variation of blood pressure: The basis for the chronotherapy of hypertension. Adv Drug Deliv Rev 2007; 69: 904-922.
29. Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: The Dublin outcome study. Hypertension 2005; 46: 156-161.
30. Dolan E, Li Y, Thijs L, McCormack P, Staessen JA, O'Brien E et al. Ambulatory arterial stiffness index: Rationale and methodology. Blood Press Monit 2006; 11: 103-105.
31. Li Y, Dolan E, Wang JG, Thijs L, Zhu DL, Staessen JA et al. Ambulatory arterial stiffness index: Determinants and outcome. Blood Press Monit 2006; 11: 107-110.
32. Kikuya M, Staessen JA, Ohkubo T, Thijs L, Metoki H, Asayama K et al. Ambulatory arterial stiffness index and 24-h ambulatory pulse pressure as predictors of mortality in Ohasama, Japan. Stroke 2007; 38:1161-1166.
33. Mayer B, Lieb W, Radke PW, Götz A, Fischer M, Bässler A et al. Association between arterial pressure and coronary artery calcification. J Hypertens 2007; 25: 1731-1738.
34. O'Brien E. Sleepers versus nonsleepers: Another-twist to the dipper/ nondipper concept. Hypertension 2007; 49: 769-770.
35. Schwartzkopff O, Halberg F, Katinas G, Cornélissen G, Otsuka K, Watanabe Y et al. Strain tests: Guaging variability in day, week, year or decade. In: Proceedings 59th Annual Meeting Japan Society of Neurovegetative Research, Tokyo, November 1-3, 2006, pp P4-68.
36. Cornélissen G, Halberg F, Bakken EE, Singh RB, Otsuka K, Tomlinson B et al. 100 or 30 years after Janeway or Bartter, Healthwatch helps avoid 'flying blind'. Biomed Pharmacother 2004; 58(Suppl 1): S69-S86.
37. De La Pena SS, Gonzalez C, Cornelissen G, Halberg F. Blood Pressure (BP), Heart Rate (HR) and Non-Insulin-Dependent Diabetes Mellitus (NIDDM) Chronobiology. Int J Cardiol 2004; 97(Suppl 2): S14.
38. Cornélissen G, Halberg F, Otsuka K, Singh RB, Chen CH. Chronobiology predicts actual and proxy outcomes when dipping fails. Hypertension 2007; 49: 237-239.
39. Halberg F, Cornélissen G, Halberg J, Schwartzkopff O. Pre-hypertensive and other variabilities also await treatment. Am J Med 2007; 120: E19-e20.
40. Després JP. Cardiovascular disease under the influence of excess visceral fat. Crit Pathw Cardiol 2007; 6: 51-59 (review).
41. Rajala MW, Scherer PE. Minireview: The adipocyte - at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003; 144: 3765-3773.
42. Moreno-Aliaga MJ, Campion J, Milagro FI, Berjon A, Martinez JA. Adiposity and proinflammatory state: The chicken or the egg. Adipocytes 2005; 1: 1-16.
43. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115: 911-919; quiz 920.
44. Vettor R, Milan G, Rossato M, Federspil G. Review article: adipocytokines and insulin resistance. Aliment Pharmacol Ther 2005; 22(Suppl 2): 3-10 (review).
45. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1785-1788.
46. Kougias P, Chai H, Lin PH, Yao Q, Lumsden AB, Chen C. Effects of adipocyte-derived cytokines on endothelial functions: Implication of vascular disease. J Surg Res 2005; 126: 121-129.